1、White PaperThe Impact of Biosimilar Competition in Europe January 2026MAX NEWTON,Principal,Global Strategic Partners,IQVIA KELSEY STODDART,Senior Consultant,Global Supplier&Association Relations,IQVIAAURELIO ARIAS,Director,Global Thought Leadership,IQVIATable of contentsIntroduction 1IQVIA observati
2、ons 21.Pipeline 42.Commercial attractiveness 63.International competitiveness 94.Access inequality 105.Advanced planning 14Methodology 16Country and product segment KPIs 18Granulocyte-Colony Stimulating Factor(GCSF)18Anti-Tumour Necrosis Factor(Anti-TNF)20Insulins 22Oncology 24Parathyroid hormone(te
3、riparatide)26Ophthalmology 28Appendix 30EMA list of approved biosimilars 30List of biosimilars under review by EMA 36References 37About the authors 38Find out more 39 |1The 11th edition of the Impact of Biosimilar Competition in Europe report builds upon the perspectives from last years publication
4、and provides a forward-looking view on the upcoming opportunities and challenges for biosimilar competition in Europe.Biosimilars continue to play a critical role in the European healthcare system by generating savings for payers,creating headroom for innovation,and expanding access to biologic ther
5、apy for patients.Since the first biosimilar was launched in 2006,biosimilar medicines have become a core component of an effective healthcare system.However,the biosimilar pipeline signals future headwinds,which have been highlighted in previous reports and remain relevant today.The report consists
6、of novel observations on market conditions for 2025,and a streamlined set of Key Performance Indicators(KPIs)to monitor the impact of biosimilars in 23 European markets.Previous observations remain relevant and have been refined or referenced to align with the reports approach of sharing novel obser
0731-84720580
商务合作：really158d
研搜
微信扫码登录
手机快捷登录
账号登录
